This NYSE Biotech Profile Is A Low Float Idea With Analyst Coverage Providing Over 275% Potential Upside
Your Full Report Arrives 9:30AM EST Wednesday
Sign Up To My SMS Update System (Directions Below)
Currently flying under Wall Street's radar, I've unearthed a new biotech profile trading on the NYSE American you need to get on your watch-list immediately.
Tomorrow at 9:30AM EST, you get the full report.
Remember Monday's Nasdaq profile DARE? Throughout the day, it battled with its: 50-Day SMA, 200-Day SMA, and 13-Day EMA.
If those levels are able to break down in the short-term, it could receive some serious buzz for a potential support-backed squeeze towards a vertical move.
Keep DARE on radar, but also get ready for this new biotech idea by checking out 3 potential catalysts now:
3 Potential Catalysts For This New NYSE American Profile
#1. A consensus price target from multiple analysts gives this NYSE idea over 275% in upside potential from current trading levels.
#2. Throughout 2020, this profile has shown the potential to deliver multi-dollar runs in the short-term. With big recent news, could this biotech's next major breakout be right around the corner?
#3. With fewer than 13Mn shares in its float, according to Yahoo Finance, volatility could create the potential for a vertical surge.
Right now, I suggest doing one thing to prepare: